At the American Thoracic Society meeting, Dr Hiroki Tateno shared the results of a randomized, sham-controlled, open-label study to evaluate the long-term efficacy of CureApp, a novel smoking cessation app (CureApp Inc.), when used in addition to pharmacotherapy.
Questions
1. What smoking cessation aids are currently available and how successful have they been in achieving their goals? (0:05)
2. Please describe what the novel mobile phone app CureApp is and how it works? (1:04)
3. Please describe how the efficacy of CureApp in Japan was assessed in a clinical trial? (2:24)
4. What were the key results of the CureApp clinical trial as compared with existing smoking cessation methods? (3:33)
5. What are the implications of this trial’s results for smoking cessation and is any further work required to bring the potential benefits to a wider group of people? (4:42)
